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WHAT THIS PAPER ADDS
 Despite the availability of multiple classes of orally active antihypertensive treatments, resistant hypertension remains an
important public health issue in 2012. The failure of purely pharmacological approaches to treat resistant hypertension has
stimulated interest in invasive device-based treatments. A new catheter system using radiofrequency energy has been developed,
allowing an endovascular approach to renal denervation and providing patients with resistant hypertensionwith a new therapeutic
option. To date, this technique has been evaluated only in open-label trials including small numbers of highly selected patients with
suitable renal artery anatomy. The beneﬁt/risk ratio of this technique remains to be evaluated.a r t i c l e i n f o
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This review aims to describe the role and the results of catheter-based renal nerve ablation for the
treatment of resistant hypertension. Despite the availability of multiple classes of orally active antihy-
pertensive treatments, resistant hypertension remains an important public health issue in 2012 due to its
prevalence and association with target-organ damage and poor prognosis. The failure of purely phar-
macological approaches to treat resistant hypertension has stimulated interest in invasive device-based
treatments based on old concepts. In the absence of orally active antihypertensive agents, patients with
severe and complicated hypertension were widely treated by surgical denervation of the kidney until the
1960s, but this approach was associated with a high incidence of severe adverse events and a high
mortality rate. A new catheter system using radiofrequency energy has been developed, allowing an
endovascular approach to renal denervation and providing patients with resistant hypertension with
a new therapeutic option that is less invasive than surgery and can be performed rapidly under local
anaesthesia. To date, this technique has been evaluated only in open-label trials including small numbers
of highly selected resistant hypertensive patients with suitable renal artery anatomy. The available
evidence suggests a favourable blood pressure-lowering effect in the short term (6 months) and a low
incidence of immediate local and endovascular complications. This follow-up period is, however, too
short for the detection of rare or late-onset adverse events. For the time being, the beneﬁt/risk ratio of
this technique remains to be evaluated, precluding its uncontrolled and widespread use in routine
practice.
 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.tension Artérielle et Centre
Pompidou, 20 rue Leblanc,
.
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ciety for Vascular Surgery. PublisheThe involvement of the autonomic nervous system, including
the renal sympathetic system, in particular, in the pathophysiology
of arterial hypertensionwas recently highlighted by the publication
of preliminary results for the use of catheter-based radiofrequencyd by Elsevier Ltd. All rights reserved.
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autonomic nervous system comprises sympathetic efferent path-
ways, which run from the hypothalamic autonomic centres to the
kidney via the sympathetic ganglia at D12 to L1, and afferent
pathways, which originate from the kidneys and run to the auto-
nomic centres.3,4 Both the efferent and afferent nerve ﬁbres follow
the renal artery to the kidney and lie primarily within the adven-
titia. The efferent renal sympathetic system plays amajor role in the
regulation of blood pressure (BP) by stimulating sodium reab-
sorption by epithelial tubular cells throughout the nephron, renin
release from the juxtaglomerular cells and renal vascular smooth
muscle cell contraction, decreasing renal blood ﬂow.3 The afferent
autonomic nerve ﬁbres originating from the kidney act as mecha-
noreceptors or chemoreceptors sensitive to renal injury (stretching
and ischaemia), but they also regulate BP by modulating posterior
hypothalamic activity, thereby affecting the overall sympathetic
outﬂow to the kidneys, heart and peripheral blood vessels.
Sympathetic nervous system overdrive may cause hypertension,
not only through its renal effects, but also by increasing cardiac
output and peripheral arterial resistance.3 Hypertensive patients
have an increased central sympathetic drive, as shown by assess-
ments of muscle sympathetic nerve activity (MSNA).5 The norepi-
nephrine spillover method has also been used to demonstrate the
activation of sympathetic nerve outﬂow to the kidneys and heart.
Renal norepinephrine spillover levels are also high in both normal-
weight patients with essential hypertension and in patients with
obesity-related hypertension.3 The degree of sympathetic activa-
tion is correlated with hypertension severity and is more marked in
patients with diabetes, obesity or metabolic syndrome. It has also
been associated with hypertension-related target-organ damage,
heart failure, chronic kidney disease and end-stage renal disease. In
various rodent or dog models of hypertension, surgical denervation
of the renal sympathetic nerve system has been shown to delay or
to prevent the occurrence of hypertension in most cases.3
History of Surgical Renal Denervation in the Treatment of
Severe and Complicated Hypertension
Surgical renal denervation came to prominence as a treatment
for severe and complicated hypertension at the end of the 1930s,
when no orally active antihypertensive treatments were available.6
The intervention consisted of splanchnicectomy, either alone or
combined with total thoracic and partial to total lumbar sympa-
thectomy and celiac ganglionectomy.7 The procedure was particu-
larly invasive, sometimes performed in two steps, 2 weeks apart,
and perioperativemortalitywas high, at about 5%.8,9 Adverse events
were frequent, disabling and long lasting, and included severe
orthostatic hypotension, sphincter incontinence, sexual dysfunction
and paradoxical excessive sweating.10 Furthermore, BP reduction
was inconsistent and observed in onlyz50% of cases.8,9 However, in
the absence of orally active antihypertensive treatments, some
beneﬁts were observed, in terms of end-organ protection and lower
levels of mortality, over a period of more than 10 years.8,9 These
effects were partly independent of BP reduction.9 This surgical
procedure was abandoned in the 1960s, when effective and much
better-tolerated orally active antihypertensive drugs became
available.11
Reasons for Renewed Interest in Device-based Treatments:
Resistant Hypertension
Despite the development of multiple classes of antihypertensive
drugs over the last 40 years, improvements in their efﬁcacy and
tolerance and the use of combination therapies, target BP is not
achieved in a signiﬁcant proportion of hypertensive patients. BPcontrol rates of 30e50% have been reported in the hypertensive
population from the United States and Europe.12,13 This poor control
of hypertension remains a major public health issue, because it
directly inﬂuences prognosis, target-organ damage and cardio- and
cerebrovascular morbidity and mortality.14 However, uncontrolled
hypertension rates overestimate the prevalence of resistant
hypertension. Indeed, international guidelines deﬁne resistant
hypertension as a failure to reach BP goal (140 and/or 90mmHg or
130 and/or 80mmHg in cases of diabetes or renal insufﬁciency) in
patients treated with an appropriate three-drug regimen, including
a diuretic, with all drugs administered at optimal doses.1517 In
tertiary care specialised centres, the prevalence of resistant
hypertension ranges from 5% to 25% of the hypertensive patients
referred.1719 The prevalence of resistant hypertension in the
general population is less well known. In the NHANES study, the
prevalence of resistant hypertension was z13% in treated hyper-
tensive patients.20 However, the prevalence of resistant hyperten-
sion, as deﬁned by ofﬁce BP measurement, is probably also
overestimated. Only 63% of the 8295 patients included in a Spanish
registry who had resistant hypertension deﬁned on the basis of
ofﬁce BP measurements had genuine resistant hypertension
conﬁrmed by 24 h-ambulatory BP monitoring (ABPM). The overall
prevalence of truly resistant hypertension in this registry was thus
7%.21 The use of ABPM or home BP measurements is therefore
strongly recommended, to conﬁrm resistant hypertension and to
exclude pseudo-resistance.17,18
BP control may be poor for several reasons, including a lack of
adherence with treatment and clinical inertia, inadequate control
of lifestyle factors, the use of other substances with potential effects
on BP and the presence of undetected causes of secondary hyper-
tension.17 Once action has been taken to detect and correct these
factors, most international guidelines recommend reducing sodium
intake and increasing the intensity of diuretic therapy in patients
with resistant hypertension with simpliﬁcation and intensiﬁcation
of the treatment and of follow-up in a specialist centre.1518 This
strengthening of BP management is deemed necessary because
resistant hypertension is associated with target-organ damage22
and poor prognosis,14 even in the short term.23
However, despite ‘optimal’ management at specialist centres,
many patients continue to display resistant hypertension, even on
combinations of several antihypertensive treatments. In this situ-
ation of pharmacological failure, invasive device-based treatment
approaches have emerged as a new option for treatment. Recent
technological progress has allowed the development of invasive
approaches, such as renal denervation1,2 and the stimulation of
carotid baroreceptors.24 We focus here on renal denervation.
Catheter-based Renal Nerve Ablation
A new catheter system has been developed, making the endo-
vascular approach to renal denervation an attractive therapeutic
option in patients with resistant hypertension. Unlike surgical
approaches to renal denervation, the endovascular approach is
selective. It is also less invasive and can be performed rapidly under
local anaesthesia, with a limited periprocedural risk.
The Symplicity Catheter System (Medtronic-Ardian) is the only
system currently available. It can be used for the selective and
sequential denervation of both kidneys, through the focal delivery
of four to six low-power radiofrequency energy ablations (5e8 W)
along the length of both renal arteries. It consists of an automated
low-power radiofrequency generator coupled to a disposable
radiofrequency catheter. Prior to the procedure, appropriate
systemic anticoagulation should be provided to the patient.
Percutaneous femoral access under local anaesthesia is used to
introduce the catheter. Selective renal artery catheterisation is
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to the arterial wall, in a zone close to the renal hilum, under
radiographic and impedance control (Fig. 1). Each renal nerve
ablation sequence lasts for 2 min. At the end of each sequence, the
probe is moved to a new position a fewmillimetres (approximately
5 mm) further back along the artery, with circumferential rotation
used to ensure that the position of the probe with respect to the
artery circumference is also changed between ablations. A series of
four to six ablations per renal artery results in stepwise renal
denervation, allowing treatment of the entire circumference of the
renal artery along a helical pathway. The energy delivered by the
radiofrequency impulses dissipates in the form of heat in the
arterial wall, particularly in the adventitia, which houses the
autonomic nerves, with blood ﬂow cooling the intima and mini-
mising endothelial injury. The radiofrequency impulses are auto-
matically adjusted by the generator, which monitors the
impedance, the energy delivered and the temperature. The energy
released during the sequential ablations may cause visceral pain,
justifying sedation/analgesia with opiates and narcotics.
The intervention is technically easier than renal artery stenting.
However, the interventionalist should always keep in mind that
those apparently healthy renal arteries may be fragile because they
have been exposed to high BP levels for a long time before dener-
vation. There is therefore an increased risk of renal artery dissection
(see below). The catheter available today is not an over-the-wire
device and, therefore, should be manipulated with caution
despite its relatively soft extremity. The use of a guiding catheter or
a long sheath can be advocated but more caution is also deemed
necessary because its extremity can be very aggressive especially
when control angiograms are performed through the side port of
the sheath. Permanent ﬂushing of the side port of the sheath/
guiding catheter with heparinised saline is recommended as well
as bolus injection of a nitroglycerine into each renal artery in order
to reduce spasm prior to the procedure.
Before renal denervation is carried out, the suitability of the
patient’s renal artery anatomy should be checked, preferably by
computed tomography (CT)- or magnetic resonance (MR)-angiog-
raphy. The ideal anatomical conditions are as follows: presence of
a single renal artery on each side, of sufﬁcient length (20 mm) and
diameter (4 mm), without stenosis, that has not previously been
subjected to angioplasty or stenting and is accessible by percuta-
neous femoral access. Renal denervation should not be performed
in the presence of a solitary functioning kidney. Ideally, the
infrarenal abdominal aorta should also be free of major lesions,
such as unstable atherosclerotic plaques, aneurism or dissection.Figure 1. A: The tip of the catheter is applied to the arterial wall, close to the hilum, for the ﬁ
5 mm and rotated before delivering the second radiofrequency ablation; 4e6 ablations in
angiogram of the right renal arteries showing the tip of the catheter applied to the arteriaAt the end of the procedure, a global angiogram of the aorta and
the renal arteries should be obtained, to check the integrity of the
renal arteries (dissection) and the renal parenchyma (infarcts).
Some irregularities of the renal artery wall can be observed after
renal denervation which do not have pathological signiﬁcance
(Fig. 2). The procedure takes 30e50 min in total, depending on the
anatomy of the renal arteries and the skills of the interventionalist
(radiologist/cardiologist/surgeon) carrying out the intervention.
The patient is then usually monitored for 24 h at the hospital.
Despite its apparent simplicity, this procedure should be carried
out exclusively at specialist centres. The interventionalist carrying
out the intervention should have sufﬁcient experience in the
selective catheterisation and angioplasty of the renal arteries, and
the necessary technical resources for the management of any
immediate complication, such as renal artery dissection in partic-
ular (see below), for which stents of larger calibre than those used
for coronary arteries may be required.
Optimal imaging capacities are also required, as denervation
requires accurate catheterisation techniques, often in obese
patients. Digital radiographic images of the renal artery before and
after denervation and of the kidney should be stored, to allow
retrospective analysis in cases of mid- and long-term complica-
tions. The images should comprise the renal arteries and paren-
chyma of both sides after completion of the denervation.
Clinical Studies of Radiofrequency-based Renal-nerve
Ablation
Two principal studies have been published on radiofrequency
renal-nerve ablation in patients with resistant hypertension. The
ﬁrst-in-man study, the Simplicity HTN1 study, evaluated the
feasibility and safety of the procedure in 50 patients and reported
encouraging BP reductions, with no major complications due to the
technique.2 This initial cohort was subsequently expanded to 153
patients.25 The second study, the Simplicity HTN2 study, was
a multicentre, open, randomised, controlled trial comparing the
antihypertensive efﬁcacy of this procedure plus drug treatment
with that of drug treatment alone, in 106 patients aged 18e85 years
with a systolic BP160mmHg (150mmHg in patients with type 2
diabetes) despite combination therapy with at least three antihy-
pertensive drugs, a creatinine clearance 45 ml min1 and a renal
artery anatomy suitable for this procedure (presence of two func-
tioning kidneys with single renal artery on each side, of sufﬁcient
length (20 mm) and diameter (4 mm), without stenosis, not
previously subjected to angioplasty or stenting).1 The studyrst radiofrequency ablation in the right renal artery. The catheter then is pulled back by
each individual renal artery are required for “optimal” renal denervation. B: Renal
l wall.
Figure 2. Selective angiogram of the right renal artery (left panel, after the 1st RF ablation) and ﬁnal global angiogram (right panel) showing some irregularities of the renal artery
wall (white arrows) after renal denervation.
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body mass index (BMI): 31 kg m2) patients (42% women, 98%
Caucasian, 34% type 2 diabetes), mostly with resistant systolic
hypertension (mean systolic BP: 178/98mmHg), 62% of whomwere
treated with at least ﬁve antihypertensive drugs. It should be noted
that the deﬁnition of resistant hypertension in this trial was not in
strict accordancewith international guidelines in terms of target BP
(>160 mmHg despite triple therapy vs. >140 and/or 90 mmHg
despite triple therapy including diuretics) and treatment (z10% of
the patients were not given diuretics and less than 20% of patients
were treated with an aldosterone antagonist, which is now rec-
ommended for the treatment of resistant hypertension17,18).
Moreover, ABPM was not required for the conﬁrmation of resistant
hypertension and no preliminary investigations to exclude
secondary hypertension were requested.
Tolerability and Safety of Radiofrequency Renal-nerve
Ablation
Both studies reported a low incidence of immediate periproce-
dural complications and short- and medium-term renal and
vascular complications (at 6e12 months). Four of the 153 patients
of the expanded cohort had immediate complications: one case of
renal-artery dissection and three pseudo-aneurysms at the femoral
artery site.25 Two patients from this cohort died during follow-up,
one from myocardial infarction and the other from sudden death
syndrome. An independent data monitoring and safety committee
decided that these deaths could not be attributed to the denerva-
tion procedure. The signiﬁcant adverse events reported in the
Simplicity HTN2 study (52 procedures) were one pseudo-aneurysm
at the femoral artery site and a case of post-procedural hypotension
reversed by decreasing the intensity of antihypertensive treat-
ment.1 No orthostatic hypotension was reported and the cardio-
pulmonary response to exercise was maintained after renal
denervation.26 A non-fatal cardio/cerebrovascular event occurred
in four of the patients undergoing renal denervation and three
patients in the control group. Finally, no signiﬁcant change in meanTable 1
Blood pressure decrease at 6 months in the two groups of the randomized controlled Sym
With denervation (n ¼ 52)
Ofﬁce blood pressure measurements 32  23/12  11 (n ¼ 49)
Self blood pressure measurements 20  17/12  11 (n ¼ 32)
24 h ABPMa 11  15/7  11 (n ¼ 20)
a AMBP: ambulatory blood pressure measurements.glomerular ﬁltration rate was observed at months, consistent with
stable renal function. The overall incidence of early adverse events
related to the procedure was 3.5%, based on the combined safety
data for the two studies (205 patients, 18 of whom had a maximal
follow-up period of 24 months).
Radiofrequency ablation is also associated with a theoretical
long-term risk of ﬁbrotic scarring that may favour the development
of focal renal artery stenoses or aneurysm. Preclinical safety studies
in pigs have shown treatment-related renal nerve injury and focal
medial and adventitial ﬁbrosis of the renal arteries, associated with
minimal intimal thickening and disruption of the internal elastic
lamina, and complete re-endothelialisation, with no inﬂammatory
cells, renal artery stenosis or thrombosis, 6 months after renal
denervation.27 In 18 patients from the Simplicity HTN1 study,
a renal angiogram performed 14e30 days after renal denervation
revealed a total absence of renal artery lesions. Imaging of the renal
arteries 6 months after the intervention, mostly by renal artery
duplex scanning, was available in 43 of 52 patients in the Simplicity
HTN2 study and 81 of 153 patients of the extended cohort study; it
showed an absence of renal artery lesions.1,25 The progression of
underlying atherosclerotic stenosis was observed in one patient
after denervation, but did not require treatment.1
In summary, these safety data are reassuring, but they were
generated from a small number of procedures performed by expert
interventionalists on highly selected patients at specialist reference
centres. They do not exclude the possibility of rare (incidence <5%)
but serious adverse events, particularly in routine practice. The risk
associated with the procedure depends largely on the careful
selection of patients eligible for renal denervation and the experi-
ence of the interventionalist carrying out the intervention, as
already reported for carotid stenting.28
Effect of Radiofrequency Nerve Ablation on Ofﬁce BP
In the Simplicity HTN2 trial, a progressive decrease in ofﬁce
systolic/diastolic BP of 32/12mmHgwas observed at 6months in 49
of the52patientswhounderwent renaldenervation,whereasBPdidplicity HTN2 trial.1 Results are reported in mmHg, as the mean  standard deviation.
Without denervation (n ¼ 54) p
þ1  21/0  10 (n ¼ 51) <0.0001/<0.0001
2  13/0  7 (n ¼ 40) <0.0001/<0.0001
3  19/1  12 (n ¼ 25) <0.006/<0.014
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Figure 3. Teletransmitted home blood pressure (BP) monitoring in a patient treated by
renal denervation. The patient had severe hypertension before renal artery denerva-
tion, despite being treated with four antihypertensive drugs. The immediate decrease
in BP on day 2 after renal denervation (day 0) is of multifactorial origin (36-h bed rest
in hospital, contrast injection, sedation, etc.) and is probably not due to the procedure
itself. When the patient returned at home, the BP decrease after renal denervation was
progressive over 60 days. Symptomatic hypotension occurred around day 65 which
imposed to stop one among four antihypertensive treatments. After 3 months, BP level
was stabilized at around 130/85 mmHg with a triple antihypertensive therapy. The
dotted line shows the BP threshold for uncontrolled hypertension using home BP
monitoring (systolic BP > 135 mmHg and/or diastolic BP > 85 mmHg).
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Table 1).1 Fig. 3 shows an example of the progressive BP decrease
achieved after renal denervation in one patient. The goal systolic BP
(<140mmHg)was reached at 6months in 39% of the patients in the
renal denervation group and 6% of the patients in the control group
(p < 0.001). Moreover, 84% of the patients undergoing renal dener-
vation displayed a decrease in systolic BP of at least 10 mm Hg,
whereas such a decrease was observed in only 35% of the controls
(p < 0.001). Antihypertensive medication was increased during
follow-up in four (8%) of the patients undergoing renal denervation
and six (12%) of the control patients (p ¼ 0.74). Conversely, antihy-
pertensive medication was decreased in 10 (20%) of the patients
undergoing renal denervation and three (6%) of the control patients
(p ¼ 0.04). Overall, the percentage of favourable responses attrib-
utable to radiofrequency renal nerve ablationwas 50%, a ﬁgure close
to the percentage of responders to surgical sympathetic denerva-
tion. Finally, it should be noted that no BP-lowering effects of renal
denervationwere observed in 10% of patients and antihypertensive
medication was never completely stopped in any of the patients.
The mechanism of BP reduction by renal denervation has been
investigated by muscle sympathetic nerve activity (MSNA) or
norepinephrine spillover measurements. In one patient, post-
ganglionic nerve trafﬁcking, as measured by peroneal nerve
microneurography, was found to have decreased 1 month after
renal denervation and normalised after 1 year, with an improve-
ment in baroreﬂex sensitivity.29 An improvement of baroreﬂex
sensitivity was also reported in our case series based on a different
methodology.30 Renal norepinephrine spillover had decreased by
50%, 15e30 days after renal denervation, in 10 patients in the pilot
study. This decrease was associated with a 30% decrease in total
body norepinephrine spillover, one-third of which was attributable
to a decrease in renal sympathetic activity.31 This effect can prob-
ably be accounted for by the ablation of afferent nerve ﬁbres from
the kidney, preventing the stimulation of autonomic centres.
However, although these data conﬁrm that renal denervation iseffective, they also indicate that the procedure only partially
reduces total sympathetic activity.
Critical Appraisal of Published Studies
Published studies are subject to several limitations inherent to
their open-label design, potentially jeopardising their internal
validity and decreasing the degree of BP reductionwe can expect to
be achieved.32 Indeed, an open-label design is subject to expecta-
tion, performance and evaluation biases, particularly in trials
evaluating the efﬁcacy of an invasive procedure, such as renal
denervation. Furthermore, the evaluation of the BP effect of renal
denervation was based on ofﬁce BP measurement, a primary
outcome that may be subject to observer bias. Such biases cannot
be ruled out even for the Simplicity HTN2 randomised controlled
trial, because the antihypertensive treatment regimen was not
standardised, compliance with treatment was not checked during
the study and the primary outcome (ofﬁce BP measurement) was
not evaluated blind to treatment allocation. Therefore, active co-
interventions (either intentional or non-intentional) and outpa-
tient visits may have been more frequent, and compliance with
treatment, dietary and a healthy lifestyle may have been more
strongly encouraged by study staff, family members or self-
motivation in patients undergoing renal denervation than in the
patients of the control group. Conversely, patients randomised to
the control groupmay have been disappointed with the continuing
lack of improvement in BP control and with not being offered ‘the
new intervention’. As these patients were aware that they could
potentially undergo renal denervation if their BP remained high at
6 months, they may have been reluctant to comply strictly with
their antihypertensive treatment regimen and with lifestyle
measures, to ensure that they received ‘the new treatment’.
Moreover, observer bias may also have inﬂuenced ofﬁce BP
measurements in opposite directions in the two randomised
groups. An investigator expecting renal denervation to be effective
may have been inclined to measure BP differently in the two
groups: for example, the resting period before ofﬁce BP measure-
ments and the number of BP measurements taken may not have
been the same in the two groups. Finally, those involved in data
analysis were not blind to treatment assignment. All these factors
may partly account for the large difference in ofﬁce BP between the
two groups in the Simplicity HTN2 trial, the absence of a decrease in
ofﬁce BP in the control group at 6 months and the large discrepancy
between the ambulatory and ofﬁce BP results. As expected, the BP-
lowering effects of renal denervation, as assessed by ABPM or self-
measurement at home, were smaller than those evaluated by ofﬁce
BP measurement. The mean decrease in ambulatory systolic BP in
the 20 of the 52 patients with valid 24-h ABPM measurements
before and 6 months after renal denervation was only 11 mmHg,
much smaller than the 32 mmHg decrease in ofﬁce systolic BP
(Table 1). Furthermore, the difference in 24-h ambulatory BP
between the two groups was only 8 mmHg, an effect similar to that
expected for the addition of a single antihypertensive agent. ABPM
is devoid of thewhite coat effect, observer bias, digit preference and
placebo effect, and providesmore reproduciblemeasurements than
ofﬁce BP measurements. It is now the cornerstone of determina-
tions of the antihypertensive efﬁcacy of new drugs, as recom-
mended by international health authorities (United States Food and
Drug Administration and European Medicines Agency). Unfortu-
nately, this method was not available to all patients of the
Simplicity HTN2 trial.
The mean decrease in BP reported in the Simplicity HNT2 study
conceals considerable heterogeneity in individual BP responses to
renal-nerve ablation, as shown by the large standard deviations of
23 and 15 mmHg associated with the decreases in ofﬁce and 24-h
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ofﬁce systolic BP being reached in only 39% of the patients and the
complete absence of a BP response in 10% of patients. This lack of
response may be due to (1) a primary failure of renal denervation,
as no imaging or functional marker of the success of this inter-
vention is currently available and/or (2) the multifactorial and
complex origin of hypertension and resistance to treatment.
Indeed, total and renal sympathetic overactivity may not be the
predominant pathogenic factor underlying hypertension and
accounting for treatment resistance in an unknown number of
patients. Thus, catheter-based renal denervation is not beneﬁcial
but is nonetheless associated with potential risks in at least 10% of
patients. Unfortunately, no speciﬁc factor predictive of the BP
response to renal denervation has been identiﬁed from the vari-
ables considered: age, sex, previous coronary events, diabetes,
dyslipidemia, BP or resting heart rate, number of classes of anti-
hypertensive drugs taken, glomerular ﬁltration rate and number of
radiofrequency ablations. In the extended cohort study, multivar-
iate analysis showed that a higher basal BP (as expected) and the
use of centrally acting antihypertensive agents were signiﬁcantly
associated with better ofﬁce BP responses.25
Another issue concerns the unknown long-term antihyperten-
sive efﬁcacy of renal denervation. Past experience with surgical
renal denervation shows that BP reduction may bemaintained over
time,8,9 but it is difﬁcult to extrapolate this ﬁnding to radio-
frequency renal-nerve ablation. Indeed, radiofrequency renal-
nerve ablation is more selective and, therefore, by deﬁnition, less
complete. The conservation of anatomical connections makes
sympathetic reinnervation possible, a phenomenon that has been
documented following renal transplantation.33 However, although
the regeneration of efferent renal-nerve ﬁbres with reinnervation
of the kidney is well recognised, there is little evidence for the
regeneration of afferent nerve ﬁbres in the kidney. This may
account for the sustained, long-term BP reduction reported in
a small subgroup of patients (23/11 mmHg for ofﬁce systolic/
diastolic BP at 12 months in 64 patients and 32/14 mmHg at 24
months for 18 patients of the expanded cohort25). These data,
which do not take the number of antihypertensive drug used into
account, are subject to the same biases as mentioned above.
Finally, the external validity of the studies may also be limited
because they included a small sample of highly selected patients. In
the Simplicity HTN2 study, z45% of the patients who agreed to
participate were excluded before randomisation because of white
coat resistance and unsuitable renal artery anatomy precluding renal
denervation in almost 20% of patients. In addition, the characteristics
of the patients e obese, Caucasian patients with resistant hyperten-
siondespite treatmentwithz5 antihypertensive drugs, a glomerular
ﬁltration rate >45 ml min1 and a suitable renal artery anatomy e
make it difﬁcult to extrapolate the results to the general population of
patients with resistant hypertension. For example, obese patients
may be more responsive to renal denervation than lean patients,
because the pathophysiology of obesity-associated hypertension
involves hyperactivity of the sympathetic nervous system, particu-
larly in patients with obstructive sleep apnea syndrome.34,35
Research Perspectives and Clinical Applications
Radiofrequency renal-nerve ablation opens up several new
possibilities for treatment.32 Various studies are already underway
for indications other than resistant hypertension, including meta-
bolic syndrome, heart failure, sleep apnea syndrome, renal insuf-
ﬁciency and diabetic nephropathy. For example, preliminary results
have suggested that renal denervation may have a beneﬁcial effect
on insulin resistance and sleep apnea syndrome.36,37 Furthermore,
new catheter systems will emerge for the renal denervation bydifferent methodologies, and these systems will have to go through
the same evaluation process. Systematic evaluation of the beneﬁt/
risk ratio of the procedure is considered necessary for each category
of patients, including those with resistant hypertension. Radio-
frequency renal-nerve ablation should therefore still be considered
to be in the evaluation process.38 In this context, there are strong
arguments against the widespread and uncontrolled use of this
procedure in routine practice: an unknown beneﬁt/risk ratio for the
treatment of resistant hypertension, inconsistency and unpredict-
ability of the BP response, absence of medical economic evaluation,
higher risk when renal denervation is performed by intervention-
alists less skilled at patient selection and performance of the
procedure. Finally, prolonged follow-up of these patients, including
non-invasive imaging (preferably MR-angiograms to avoid excess
irradiation due to repeated CT-scanners), is essential to assess the
long-term adverse effects of renal denervation by radiofrequency
energy ablation in healthy renal arteries. To emphasise this point,
the release of a new antihypertensive drug onto the market
requires testing on several thousands of patients over several
months, followed by continuous and indeﬁnite post-release
surveillance. The best way to ensure the rigorous follow-up of
patients after renal denervationwould therefore be to include them
in clinical trials or international registries.
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